(7Z,16E)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (7Z,16E)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
• 化学式: C₂₄H₃₆N₄O₆S₂
• 分子量: 540.7
• InChiKey: OHRURASPPZQGQM-GPUWNBPISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  36
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  193
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Therapeutic agent for soft tissue sarcoma
  申请人：Astellas Pharma Inc.

  公开号：EP2238982A2

  公开（公告）日：2010-10-13

  A compound of formula I: a thiol form of the compound of formula I having a reduced S-S bond, a pharmaceutically acceptable salt of the compound of formula I, a hydrate of the compound of formula I, an anhydrous form of the compound of formula I, an acetylated form of the compound of formula I, a stereoisomer of the compound of formula I, or a mixture of said stereoisomers, for use in treatment of malignant fibrous histocytoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, fibrosarcoma, malignant schwannoma, angiosarcoma or clear cell sarcoma.

  式 I 的化合物： 具有还原型 S-S 键的式 I 化合物的硫醇形式、式 I 化合物的药学上可接受的盐、式 I 化合物的水合物、式 I 化合物的无水形式、式 I 化合物的乙酰化形式、式 I 化合物的立体异构体或上述立体异构体的混合物，用于治疗恶性纤维组织细胞瘤、脂肪肉瘤、横纹肌瘤、式 I 化合物的立体异构体或上述立体异构体的混合物，用于治疗恶性纤维组织细胞瘤、脂肪肉瘤、横纹肌肉瘤、亮肌肉瘤、纤维肉瘤、恶性肉芽肿、血管肉瘤或透明细胞肉瘤。
• Isolated bacterial strain of the genus Burkholderia and pesticidal metabolites therefrom
  申请人：MARRONE BIO INNOVATIONS, INC.

  公开号：US11382331B2

  公开（公告）日：2022-07-12

  A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural products derived from a culture of said species and methods of controlling pests using said natural products.

  本发明提供了一种Burkholderia属的菌种，其对脊椎动物没有已知的致病性，但具有杀虫活性（例如，针对植物、昆虫、真菌、杂草和线虫）。此外，本发明还提供了由所述菌种培养获得的天然产物，以及利用所述天然产物进行害虫防治的方法。
• Antitumor agent
  申请人：Naoe Yoshinori

  公开号：US20050070467A1

  公开（公告）日：2005-03-31

  The present invention relates to an antitumor agent containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination, and an enhancer of antitumor effect of topoisomerase II inhibitor, which contains a histone deacetylase inhibitor as an active ingredient. The present invention provides an antitumor agent having superior antitumor activity, which is associated with a fewer side effects.

  本发明涉及一种含有组蛋白去乙酰化酶抑制剂和拓扑异构酶 II 抑制剂组合的抗肿瘤剂，以及一种拓扑异构酶 II 抑制剂抗肿瘤效果增强剂，其中含有组蛋白去乙酰化酶抑制剂作为活性成分。本发明提供了一种抗肿瘤剂，它具有卓越的抗肿瘤活性，而且副作用较小。
• ISOLATED BACTERIAL STRAIN OF THE GENUS BURKHOLDERIA AND PESTICIDAL METABOLITES THEREFROM
  申请人：Marrone Bio Innovations, Inc.

  公开号：EP2539432B1

  公开（公告）日：2017-04-12
• Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor
  申请人：Sasakawa Yuka

  公开号：US20080233562A1

  公开（公告）日：2008-09-25

  The present invention provides a method of obtaining a gene capable of becoming an index for predicting the efficacy of a histone deacetylase inhibitor, which comprises at least (I) a step of dividing tumor cells into a histone deacetylase inhibitor sensitive tumor cell and a histone deacetylase inhibitor resistant tumor cell, and (II) a step of examining the gene expression pattern of each of the sensitive tumor cell and the resistant tumor cell, and a step of selecting (i) a gene showing high expression in the sensitive tumor cell and low expression in the resistant tumor cell, or (ii) a gene showing low expression in the sensitive tumor cell and high expression in the resistant tumor cell, in order to provide a gene useful for predicting the efficacy, particularly an antitumor effect, of a histone deacetylase inhibitor, for a tumor desired to be treated.